Matching articles for "Oluminat"
Issue 1614 · December 28, 2020 Free
An EUA for Baricitinib (Olumiant) for COVID-19

The oral Janus kinase (JAK) inhibitor baricitinib ( Olumiant – Lilly) has been granted an FDA Emergency Use Authorization (EUA) for treatment of confirmed or suspected COVID-19 in hospitalized patients ≥2…

Med Lett Drugs Ther. 2020 Dec 28; 62(1614):202-3
The oral Janus kinase (JAK) inhibitor baricitinib ( Olumiant – Lilly) has been granted an FDA Emergency Use Authorization (EUA) for treatment of confirmed or suspected COVID-19 in hospitalized patients ≥2 years old who require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO); the EUA requires that baricitinib be used in combination with the IV antiviral drug remdesivir (Veklury) . Baricitinib has been available for treatment of rheumatoid arthritis since 2018. Remdesivir was recently approved by the FDA for treatment of COVID-19 in hospitalized patients ≥12 years old who weigh ≥40 kg; it is available under an EUA for treatment of other hospitalized patients.